alfuzosin has been researched along with Urinary Retention in 38 studies
alfuzosin: structure given in first source
Urinary Retention: Inability to empty the URINARY BLADDER with voiding (URINATION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the efficacy of Alfuzosin XL 10 mg once daily for the acute management of acute urinary retention (AUR) with placebo in patients with benign prostatic hyperplasia (BPH) and to determine the predictors that impact this." | 9.14 | Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia. ( Consigliere, D; Li, MK; Macalalag, M; Tibung, MJ; Tiong, HY, 2009) |
| "To evaluate the effect of alfuzosin 10 mg once daily administered for 2 years on progression events in men with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH)." | 9.12 | Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. ( Roehrborn, CG, 2006) |
| "We confirmed the beneficial effect of the alpha1-blocker alfuzosin for the acute management of acute urinary retention (AUR) related to benign prostate hyperplasia (BPH), and further identified factors influencing the success of a trial without catheter (TWOC)." | 9.11 | Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. ( Hargreave, TB; McNeill, SA, 2004) |
| "To study the impact of alfuzosin 10 mg once daily (OD) on the outcome of a trial without catheter (TWOC) after a first episode of acute urinary retention (AUR) related to benign prostatic hyperplasia (BPH) and the subsequent management of BPH in these patients." | 9.11 | Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study. ( Hargreave, TB; McNeill, SA; Roehrborn, CG, 2005) |
| "To examine the efficacy and safety of a once-daily formulation of alfuzosin in a pooled analysis of three parallel, randomized, double-blind, placebo-controlled 3-month studies of patients with lower urinary tract symptoms (LUTS) consistent with clinical benign prostatic hyperplasia." | 9.10 | Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. ( Nordling, J; Roehrborn, CG; Van Kerrebroeck, P, 2003) |
| "In a prospective, randomized, placebo-controlled trial, 81 patients with acute urinary retention related to benign prostatic obstruction received either SR alfuzosin (n=40), an alpha1-selective blocker, given at a dose of 5 mg twice daily, or placebo (n=41) for 48 h." | 9.09 | Sustained-release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo-controlled. ( Daruwala, PD; Hargreave, TB; McNeill, SA; Mitchell, ID; Shearer, MG, 1999) |
| "As we have previously published 4 articles reporting the treatment of 7,093 clinical benign prostatic hyperplasia (BPH) patients treated with alfuzosin in a 3-month open-labelled study which was subsequently extended to 12, 24, and 36 months, the objective of this article is to provide additional data on dropouts, acute urinary retention (AUR), progression to surgery, and safety under the natural conditions of general practice, paying special attention to the predictive factors." | 9.09 | History of 7,093 patients with lower urinary tract symptoms related to benign prostatic hyperplasia treated with alfuzosin in general practice up to 3 years. ( Comet, D; Grange, JC; Lukacs, B; McCarthy, C, 2000) |
| "Alfusozine and carbachol/diazepam had no apparent benefit on the incidence of postoperative urinary retention." | 9.08 | Prevention of urinary retention after general surgery: a controlled trial of carbachol/diazepam versus alfusozine. ( Boutkan, H; Breslau, PJ; Burger, DH; Kappetein, AP, 1997) |
| "In order to assess the efficacy and safety of alfuzosin, a selective alpha-1 receptor antagonist, 205 patients with Benign Prostatic Hyperplasia (BPH) were randomly assigned in a double-blind, placebo-controlled manner, to receive either alfuzosin 2." | 9.07 | Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. ALFECH Study Group. ( Hansen, BJ; Mensink, HJ; Meyhoff, HH; Nordling, J; Walter, S, 1994) |
| "To address the long-term results of alfuzosin, an alpha 1-antagonist, in patients with benign prostatic hyperplasia (BPH)." | 9.07 | Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey. BPHALF Group. ( Attali, P; Bensadoun, H; Delauche-Cavallier, MC; Jardin, A; Stalla-Bourdillon, A, 1994) |
| "To study the efficiency of using alfuzosin 10 mg (Alfuprost MR, SUN Pharma) in routine clinical practice in order to predict its feasibility for treating acute urinary retention." | 7.96 | [The use of alfuzosin in the treatment of patients with acute urinary retention]. ( Ergakov, DV; Martov, AG, 2020) |
| "Assess safety and efficacy of 10-mg prolonged-release alfuzosin (Xatral XL) in benign prostatic hyperplasia (BPH) patients with lower urinary tract symptoms (LUTS)." | 7.75 | Safety and efficacy of a prolonged-release formulation of alfuzosin 10 mg once daily in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. ( Chodchoy, V; Kongkanand, A; Lojanapiwat, B; Pumpaisanchai, S; Ratana-Olarn, K; Sae-Tang, P; Taweemonkongsap, T, 2009) |
| "To assess the 3-year efficacy and safety of the selective alpha(1)-blocker alfuzosin at 10 mg once daily in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in 'real-life practice'." | 7.74 | Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice. ( Alcaraz, A; Elhilali, M; Emberton, M; Hartung, R; Harving, N; Matzkin, H; Vallancien, G; van Moorselaar, RJ, 2008) |
| "We analyzed the influence of treatment response on the risk of acute urinary retention and benign prostatic hyperplasia related surgery in 5,792 men complaining of lower urinary tract symptoms who were treated for 6 months with the selective alpha1-blocker alfuzosin at 10 mg once daily." | 7.73 | Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms. ( Alcaraz, A; Elhilali, M; Emberton, M; Lukacs, B; Matzkin, H; Vallancien, G, 2006) |
| "To calculate the economic consequences of using alfuzosin 10 mg once daily for managing acute urinary retention (AUR) related to benign prostatic hyperplasia (BPH)." | 7.73 | The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6-month analysis. ( Annemans, L; Cleemput, I; Hargreave, T; Lamotte, M; McNeill, A, 2005) |
| "To compare the efficacy and safety of tamsulosin and alfuzosin in patients with acute urinary retention (AUR) secondary to benign prostatic hyperplasia (BPH)." | 5.19 | A comparative study on the use of tamsulosin versus alfuzosin in spontaneous micturition recovery after transurethral catheter removal in patients with benign prostatic growth. ( Carrillo-Ruiz, JD; González-Valle, JC; Guzman-Esquivel, J; Labra-Salgado, IR; Maldonado-Ávila, M; Manzanilla-García, HA; Rosas-Nava, E; Sierra-Ramírez, JA, 2014) |
| "To compare the efficacy and safety of single (tamsulosin) and double dose (tamsulosin + alfuzosin) alpha-blocker therapy for treating catheterized patients with acute urinary retention (AUR) due to benign prostatic hyperplasia (BPH)." | 5.19 | Is the double dose alpha-blocker treatment superior than the single dose in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia? ( Kara, O; Yazici, M, 2014) |
| "To compare the efficacy of Alfuzosin XL 10 mg once daily for the acute management of acute urinary retention (AUR) with placebo in patients with benign prostatic hyperplasia (BPH) and to determine the predictors that impact this." | 5.14 | Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia. ( Consigliere, D; Li, MK; Macalalag, M; Tibung, MJ; Tiong, HY, 2009) |
| "To evaluate the effect of alfuzosin 10 mg once daily administered for 2 years on progression events in men with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH)." | 5.12 | Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. ( Roehrborn, CG, 2006) |
| "We confirmed the beneficial effect of the alpha1-blocker alfuzosin for the acute management of acute urinary retention (AUR) related to benign prostate hyperplasia (BPH), and further identified factors influencing the success of a trial without catheter (TWOC)." | 5.11 | Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. ( Hargreave, TB; McNeill, SA, 2004) |
| "To study the impact of alfuzosin 10 mg once daily (OD) on the outcome of a trial without catheter (TWOC) after a first episode of acute urinary retention (AUR) related to benign prostatic hyperplasia (BPH) and the subsequent management of BPH in these patients." | 5.11 | Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study. ( Hargreave, TB; McNeill, SA; Roehrborn, CG, 2005) |
| "To examine the efficacy and safety of a once-daily formulation of alfuzosin in a pooled analysis of three parallel, randomized, double-blind, placebo-controlled 3-month studies of patients with lower urinary tract symptoms (LUTS) consistent with clinical benign prostatic hyperplasia." | 5.10 | Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. ( Nordling, J; Roehrborn, CG; Van Kerrebroeck, P, 2003) |
| "In a prospective, randomized, placebo-controlled trial, 81 patients with acute urinary retention related to benign prostatic obstruction received either SR alfuzosin (n=40), an alpha1-selective blocker, given at a dose of 5 mg twice daily, or placebo (n=41) for 48 h." | 5.09 | Sustained-release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo-controlled. ( Daruwala, PD; Hargreave, TB; McNeill, SA; Mitchell, ID; Shearer, MG, 1999) |
| "As we have previously published 4 articles reporting the treatment of 7,093 clinical benign prostatic hyperplasia (BPH) patients treated with alfuzosin in a 3-month open-labelled study which was subsequently extended to 12, 24, and 36 months, the objective of this article is to provide additional data on dropouts, acute urinary retention (AUR), progression to surgery, and safety under the natural conditions of general practice, paying special attention to the predictive factors." | 5.09 | History of 7,093 patients with lower urinary tract symptoms related to benign prostatic hyperplasia treated with alfuzosin in general practice up to 3 years. ( Comet, D; Grange, JC; Lukacs, B; McCarthy, C, 2000) |
| "Two placebo-controlled studies involving 588 patients (292 receiving SR alfuzosin 5 mg twice daily and 296 a placebo) were pooled; 51% of the patients were > or = 65 years of age and 43% had associated cardiovascular disease including hypertension and/or were receiving concomitant antihypertensive drugs." | 5.08 | Clinical uroselectivity: evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction. ( Buzelin, JM; Delauche-Cavallier, MC; Geffriaud-Ricouard, C; Roth, S; Santoni, JP, 1997) |
| "Alfusozine and carbachol/diazepam had no apparent benefit on the incidence of postoperative urinary retention." | 5.08 | Prevention of urinary retention after general surgery: a controlled trial of carbachol/diazepam versus alfusozine. ( Boutkan, H; Breslau, PJ; Burger, DH; Kappetein, AP, 1997) |
| "To address the long-term results of alfuzosin, an alpha 1-antagonist, in patients with benign prostatic hyperplasia (BPH)." | 5.07 | Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey. BPHALF Group. ( Attali, P; Bensadoun, H; Delauche-Cavallier, MC; Jardin, A; Stalla-Bourdillon, A, 1994) |
| "In order to assess the efficacy and safety of alfuzosin, a selective alpha-1 receptor antagonist, 205 patients with Benign Prostatic Hyperplasia (BPH) were randomly assigned in a double-blind, placebo-controlled manner, to receive either alfuzosin 2." | 5.07 | Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. ALFECH Study Group. ( Hansen, BJ; Mensink, HJ; Meyhoff, HH; Nordling, J; Walter, S, 1994) |
| "To study the efficiency of using alfuzosin 10 mg (Alfuprost MR, SUN Pharma) in routine clinical practice in order to predict its feasibility for treating acute urinary retention." | 3.96 | [The use of alfuzosin in the treatment of patients with acute urinary retention]. ( Ergakov, DV; Martov, AG, 2020) |
| "Assess safety and efficacy of 10-mg prolonged-release alfuzosin (Xatral XL) in benign prostatic hyperplasia (BPH) patients with lower urinary tract symptoms (LUTS)." | 3.75 | Safety and efficacy of a prolonged-release formulation of alfuzosin 10 mg once daily in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. ( Chodchoy, V; Kongkanand, A; Lojanapiwat, B; Pumpaisanchai, S; Ratana-Olarn, K; Sae-Tang, P; Taweemonkongsap, T, 2009) |
| "To assess the 3-year efficacy and safety of the selective alpha(1)-blocker alfuzosin at 10 mg once daily in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in 'real-life practice'." | 3.74 | Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice. ( Alcaraz, A; Elhilali, M; Emberton, M; Hartung, R; Harving, N; Matzkin, H; Vallancien, G; van Moorselaar, RJ, 2008) |
| "To calculate the economic consequences of using alfuzosin 10 mg once daily for managing acute urinary retention (AUR) related to benign prostatic hyperplasia (BPH)." | 3.73 | The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6-month analysis. ( Annemans, L; Cleemput, I; Hargreave, T; Lamotte, M; McNeill, A, 2005) |
| "We analyzed the influence of treatment response on the risk of acute urinary retention and benign prostatic hyperplasia related surgery in 5,792 men complaining of lower urinary tract symptoms who were treated for 6 months with the selective alpha1-blocker alfuzosin at 10 mg once daily." | 3.73 | Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms. ( Alcaraz, A; Elhilali, M; Emberton, M; Lukacs, B; Matzkin, H; Vallancien, G, 2006) |
| "To assess the predictors of acute urinary retention (AUR) and/or surgery related to benign prostatic hyperplasia (BPH) in 3514 men complaining of lower urinary tract symptoms and treated for 6 months with the selective alpha1-blocker alfuzosin at 10 mg once daily." | 3.73 | Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily. ( Alcaraz, A; Elhilali, M; Emberton, M; Hartung, R; Harving, N; Matzkin, H; Vallancien, G; van Moorselaar, J, 2005) |
| "To determine the effectiveness of alfuzosin on symptom reduction, patients' perceived health-related quality of life (HRQL) improvement, adverse outcomes, treatment failure, and progression to acute urinary retention and prostate surgery in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH) in a 1-year prospective, open-labeled study." | 3.70 | One-year follow-up of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire. BPM Group in General Practice. ( Comet, D; Grange, JC; Lukacs, B, 2000) |
| "The aetiology of AUR was benign prostatic hyperplasia (BPH) in 29 patients and constipation in the remaining 2 patients." | 2.72 | A prospective pilot study to validate the management protocol for patients presenting with acute urinary retention: a community-based, nonhospitalised protocol. ( Byrne, DJ; Goodman, CM; Gopi, SS; Robertson, A, 2006) |
| "Acute urinary retention is a urological emergency in men and requires urgent catheterisation." | 2.50 | The role of alpha blockers prior to removal of urethral catheter for acute urinary retention in men. ( Fisher, E; Omar, MI; Subramonian, K, 2014) |
| "Acute urinary retention is a urological emergency in men and requires urgent catheterisation." | 2.45 | Alpha blockers prior to removal of a catheter for acute urinary retention in adult men. ( Subramonian, K; Zeif, HJ, 2009) |
| "The progression of benign prostatic hyperplasia (BPH) can be defined as a deterioration of clinical variables such as lower urinary tract symptoms (LUTS), health-related quality of life and peak flow rate, increased prostate size, or unfavourable outcomes such as acute urinary retention (AUR) and BPH-related surgery." | 2.43 | The natural history of benign prostatic hyperplasia. ( Fitzpatrick, JM, 2006) |
| "As alfuzosin has been shown to reduce PVR, this factor may help prevent recurrent retention following TWOC." | 2.41 | Does acute urinary retention respond to alpha-blockers alone? ( McNeill, SA, 2001) |
| " Alfuzosin 10 mg was well tolerated; the most common adverse event related to vasodilatation was dizziness/postural dizziness (3." | 1.33 | Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in 'real-life' practice. ( Alcaraz, A; Elhilali, M; Emberton, M; Hartung, R; Harving, N; Matzkin, H; Vallancien, G; van Moorselaar, RJ, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (18.42) | 18.2507 |
| 2000's | 27 (71.05) | 29.6817 |
| 2010's | 3 (7.89) | 24.3611 |
| 2020's | 1 (2.63) | 2.80 |
| Authors | Studies |
|---|---|
| Martov, AG | 1 |
| Ergakov, DV | 1 |
| Maldonado-Ávila, M | 1 |
| Manzanilla-García, HA | 1 |
| Sierra-Ramírez, JA | 1 |
| Carrillo-Ruiz, JD | 1 |
| González-Valle, JC | 1 |
| Rosas-Nava, E | 1 |
| Guzman-Esquivel, J | 1 |
| Labra-Salgado, IR | 1 |
| Fisher, E | 1 |
| Subramonian, K | 2 |
| Omar, MI | 1 |
| Kara, O | 1 |
| Yazici, M | 1 |
| Kongkanand, A | 1 |
| Chodchoy, V | 1 |
| Lojanapiwat, B | 1 |
| Pumpaisanchai, S | 1 |
| Ratana-Olarn, K | 1 |
| Sae-Tang, P | 1 |
| Taweemonkongsap, T | 1 |
| Tiong, HY | 1 |
| Tibung, MJ | 1 |
| Macalalag, M | 1 |
| Li, MK | 1 |
| Consigliere, D | 1 |
| Zeif, HJ | 1 |
| Shah, T | 2 |
| Palit, V | 2 |
| Biyani, S | 1 |
| Elmasry, Y | 2 |
| Puri, R | 2 |
| Flannigan, GM | 2 |
| Roehrborn, CG | 4 |
| Van Kerrebroeck, P | 1 |
| Nordling, J | 2 |
| Wyllie, MG | 1 |
| McNeill, SA | 4 |
| Hargreave, TB | 3 |
| McNeill, AS | 2 |
| Rizvi, S | 1 |
| Byrne, DJ | 2 |
| Jefferson, K | 1 |
| Okeke, A | 1 |
| Persad, R | 1 |
| Taylor, J | 1 |
| Biyani, CS | 2 |
| Browning, AJ | 1 |
| Emberton, M | 5 |
| Elhilali, M | 4 |
| Matzkin, H | 4 |
| Harving, N | 3 |
| van Moorselaar, J | 1 |
| Hartung, R | 3 |
| Alcaraz, A | 4 |
| Vallancien, G | 4 |
| Annemans, L | 1 |
| Cleemput, I | 1 |
| Lamotte, M | 1 |
| McNeill, A | 1 |
| Hargreave, T | 1 |
| Sarkar, R | 1 |
| van Moorselaar, RJ | 2 |
| Fitzpatrick, JM | 1 |
| Desgrandchamps, F | 1 |
| De La Taille, A | 1 |
| Doublet, JD | 1 |
| Lukacs, B | 3 |
| Mariappan, P | 1 |
| Brown, DJ | 1 |
| Gopi, SS | 1 |
| Goodman, CM | 1 |
| Robertson, A | 1 |
| Hansen, BJ | 1 |
| Mensink, HJ | 1 |
| Walter, S | 1 |
| Meyhoff, HH | 1 |
| Jardin, A | 2 |
| Bensadoun, H | 2 |
| Delauche-Cavallier, MC | 3 |
| Stalla-Bourdillon, A | 1 |
| Attali, P | 2 |
| Buzelin, JM | 2 |
| Roth, S | 1 |
| Geffriaud-Ricouard, C | 1 |
| Santoni, JP | 1 |
| Burger, DH | 1 |
| Kappetein, AP | 1 |
| Boutkan, H | 1 |
| Breslau, PJ | 1 |
| Delauche Cavallier, MC | 1 |
| Martin, D | 1 |
| Angel, I | 1 |
| Daruwala, PD | 1 |
| Mitchell, ID | 1 |
| Shearer, MG | 1 |
| Grange, JC | 2 |
| Comet, D | 2 |
| McCarthy, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prophylactic Tamsulosin in Prevention of Post-operative Urinary Retention in Men After Transanal Endoscopic Microsurgery: A Multicenter Randomized, Double-blind, Placebo-controlled Clinical Trial[NCT03314025] | Phase 2 | 158 participants (Anticipated) | Interventional | 2017-10-06 | Recruiting | ||
| Long-Term, Efficacy and Safety of Alfuzosin 10 MG OD on the Risk of Acute Urinary Retention and the Need for Surgery in Patients With BPH. A Two Year, Randomized, Multicenter, Double-Blind, Parallel Group, Placebo-Controlled Study.[NCT00029822] | Phase 3 | 1,522 participants (Actual) | Interventional | 2001-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for alfuzosin and Urinary Retention
| Article | Year |
|---|---|
The role of alpha blockers prior to removal of urethral catheter for acute urinary retention in men.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Adult; Device Removal; Doxazosin; Humans; Indoles; Male | 2014 |
Alpha blockers prior to removal of a catheter for acute urinary retention in adult men.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Adult; Device Removal; Humans; Male; Quinazolines; Rand | 2009 |
The natural history of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Age Factors; Aged; Aged, 80 and over; Controlled Clinical Trials as To | 2006 |
Definition of at-risk patients: dynamic variables.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Disease Progression; Humans; M | 2006 |
Does acute urinary retention respond to alpha-blockers alone?
Topics: Acute Disease; Adrenergic alpha-Antagonists; Humans; Male; Prostatic Hyperplasia; Quinazolines; Trea | 2001 |
18 trials available for alfuzosin and Urinary Retention
| Article | Year |
|---|---|
A comparative study on the use of tamsulosin versus alfuzosin in spontaneous micturition recovery after transurethral catheter removal in patients with benign prostatic growth.
Topics: Acute Disease; Adrenergic alpha-1 Receptor Antagonists; Aged; Device Removal; Humans; Male; Middle A | 2014 |
Is the double dose alpha-blocker treatment superior than the single dose in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia?
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Dizziness; Drug Therapy, Combinati | 2014 |
Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Double-Blind Method; Humans; Male; Prostatic Hype | 2009 |
Randomised, placebo controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary retention.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Catheterization; Delayed-Actio | 2002 |
Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Double-Blind Method; Erectile Dysfunct | 2003 |
Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Drug Administration Schedule; Humans; Male; Middl | 2004 |
Prostate size influences the outcome after presenting with acute urinary retention.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Cohort Studies; Follow-Up Studies; Humans; Male; | 2004 |
Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Biomarkers; Combined Modality Therapy; Disease-Fr | 2005 |
Three months' treatment with the alpha1-blocker alfuzosin does not affect total or transition zone volume of the prostate.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Confidence Intervals; Dose-Response Relations | 2006 |
Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.
Topics: Adrenergic alpha-Antagonists; Aged; Disease Progression; Double-Blind Method; Humans; Male; Middle A | 2006 |
A prospective pilot study to validate the management protocol for patients presenting with acute urinary retention: a community-based, nonhospitalised protocol.
Topics: Adrenergic alpha-Antagonists; Aged; Catheterization; Community Health Services; Humans; Male; Middle | 2006 |
Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. ALFECH Study Group.
Topics: Adrenergic alpha-Antagonists; Aged; Double-Blind Method; Humans; Male; Middle Aged; Prostatic Hyperp | 1994 |
Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey. BPHALF Group.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Follow-Up Studies; Heart Rate; Humans; Long-Term | 1994 |
Clinical uroselectivity: evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction.
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases | 1997 |
Prevention of urinary retention after general surgery: a controlled trial of carbachol/diazepam versus alfusozine.
Topics: Adrenergic alpha-Antagonists; Aged; Carbachol; Diazepam; Double-Blind Method; Drug Therapy, Combinat | 1997 |
Sustained-release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo-controlled.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Delayed-Action Preparations; Follow-Up Studie | 1999 |
History of 7,093 patients with lower urinary tract symptoms related to benign prostatic hyperplasia treated with alfuzosin in general practice up to 3 years.
Topics: Adrenergic alpha-Antagonists; Aged; Cohort Studies; Disease Progression; Family Practice; Follow-Up | 2000 |
Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Drug Evaluation; Humans; Male; Middle Aged; P | 1991 |
15 other studies available for alfuzosin and Urinary Retention
| Article | Year |
|---|---|
[The use of alfuzosin in the treatment of patients with acute urinary retention].
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Pro | 2020 |
Safety and efficacy of a prolonged-release formulation of alfuzosin 10 mg once daily in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Delayed-Action Preparations; Ejaculati | 2009 |
Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.
Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Humans; Male; Prostatic Hyperplasia; Quinazolines | 2003 |
Re: alfuzosin once daily facilitates return to voiding in patients in acute urinary retention.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Drug Administration Schedule; Humans; Quinazolines; Uri | 2005 |
Re: Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Drug Administration Schedule; Humans; Quinazolines; Uri | 2005 |
Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Drug Administration Sch | 2005 |
The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6-month analysis.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Decision Support Techniques; Drug Costs; Emergency Treatm | 2005 |
Long term follow up of men with Alfuzosin who voided successfully following acute urinary retention*.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Follow-Up Studies; Humans; Male; Quality of Life; Quina | 2005 |
Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in 'real-life' practice.
Topics: Adrenergic alpha-Antagonists; Aged; Ejaculation; Humans; Libido; Male; Middle Aged; Patient Satisfac | 2006 |
The management of acute urinary retention in France: a cross-sectional survey in 2618 men with benign prostatic hyperplasia.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Catheters, Indwelling; | 2006 |
Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Drug Administration Schedule; Humans; Male; Middl | 2006 |
Intravesical prostatic protrusion is better than prostate volume in predicting the outcome of trial without catheter in white men presenting with acute urinary retention: a prospective clinical study.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Endosonography; Humans; Male; | 2007 |
Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
Topics: Adrenergic alpha-Antagonists; Aged; Disease Progression; Erectile Dysfunction; Humans; Male; Nocturi | 2008 |
Clinical uroselectivity: evidence from patients treated with slow release alfuzosin for symptomatic benign prostatic obstruction.
Topics: Adrenergic alpha-Antagonists; Animals; Blood Pressure; Delayed-Action Preparations; Dose-Response Re | 1998 |
One-year follow-up of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire. BPM Group in General Practice.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Family Practice; Follow-Up Studies; Humans; M | 2000 |